CVRx Inc. is a commercial-stage medical device company. It focused on developing, manufacturing and commercializing neuromodulation solutions for patients with cardiovascular diseases. CVRx Inc. is headquartered in Minneapolis, MN.
| Revenue (Most Recent Fiscal Year) | $51.29M |
| Net Income (Most Recent Fiscal Year) | $-59.97M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 5.17 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 4.88 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -95.67% |
| Net Margin (Trailing 12 Months) | -95.61% |
| Return on Equity (Trailing 12 Months) | -79.31% |
| Return on Assets (Trailing 12 Months) | -40.96% |
| Current Ratio (Most Recent Fiscal Quarter) | 11.99 |
| Quick Ratio (Most Recent Fiscal Quarter) | 10.78 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.85 |
| Inventory Turnover (Trailing 12 Months) | 0.76 |
| Book Value per Share (Most Recent Fiscal Quarter) | $2.93 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.57 |
| Earnings per Share (Most Recent Fiscal Year) | $-2.65 |
| Diluted Earnings per Share (Trailing 12 Months) | $-2.10 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Medical Devices |
| Common Shares Outstanding | 26.15M |
| Free Float | 22.52M |
| Market Capitalization | $282.70M |
| Average Volume (Last 20 Days) | 0.20M |
| Beta (Past 60 Months) | 1.26 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 13.90% |
| Percentage Held By Institutions (Latest 13F Reports) | 75.27% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |